CompletedPHASE2, PHASE3NCT01037231
Phase 2/3 Oxabact Study
Studying Primary hyperoxaluria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- OxThera
- Principal Investigator
- Dawn Milliner, M.D., M.DMayo Clinic
- Intervention
- Oxalobacter formigenes(biological)
- Enrollment
- 36 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2009 – 2011
Study locations (3)
- Mayo Clinic (Department of Pediatric Nephrology), Rochester, Minnesota, United States
- University Children's Hospital (Division of Pediatric Nephrology), Cologne, Germany
- Academy Medical Center, University of Amsterdam, Amsterdam, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01037231 on ClinicalTrials.govOther trials for Primary hyperoxaluria
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06839235Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)Arbor Biotechnologies
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06892301Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)Guangzhou Women and Children's Medical Center
- RECRUITINGEARLY PHASE1NCT06511349Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)RenJi Hospital
- RECRUITINGNCT06225882Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.Hospices Civils de Lyon
- ACTIVE NOT RECRUITINGNCT04982393BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)Alnylam Pharmaceuticals
- RECRUITINGPHASE2NCT04580420Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRDDicerna Pharmaceuticals, Inc., a Novo Nordisk company